Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
- Conditions
- Lymphoma, Follicular
- Interventions
- Drug: R2-MANTDrug: R-MANT
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 128
- Registration Number
- NCT02390869
- Locations
- 🇮🇹
ASST Valle Olona - Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Varese, Italy
🇮🇹AO Santa Croce e Carle, Cuneo, Italy
🇮🇹Ospedale C. e G. Mazzoni UOS Ematologia, Ascoli Piceno, Italy
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
- Conditions
- Diffuse, Large B-Cell, Lymphoma
- Interventions
- Drug: GA101_DHAP
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 29
- Registration Number
- NCT02374424
- Locations
- 🇮🇹
Ospedale di Bolzano, Reparto di Ematologia & CTMO, Bolzano, Italy
🇮🇹Ematologia Policlinico San Matteo, Pavia, Italy
🇮🇹Policlinico Umberto I - Università "La Sapienza", Roma, Italy
Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- Drug: R-DHAP/R-ICE
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 135
- Registration Number
- NCT02371161
- Locations
- 🇮🇹
IRST Meldola, Meldola, Forlì-Cesena, Italy
🇮🇹Centro di Riferimento Oncologico, Aviano, PN, Italy
🇮🇹Azienda Ospaliero Universitaria di Parma, Parma, PR, Italy
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- Drug: Bortezomib-Rituximab-Bendamustine
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 38
- Registration Number
- NCT02371148
- Locations
- 🇮🇹
Ospedale S. Giacomo di Castelfranco Veneto, Castelfranco Veneto, Treviso, Italy
🇮🇹Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, PZ, Italy
🇮🇹A.O. Bianchi - Melacrino - Morelli, Reggio Calabria, RC, Italy
Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 1300
- Registration Number
- NCT02364050
- Locations
- 🇮🇹
Azienda Ospedaliera Caravaggio, Treviglio, Bergamo, Italy
🇮🇹IRCCS Humanitas, Rozzano, Milano, Italy
🇮🇹CRO-Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 300
- Registration Number
- NCT02354313
- Locations
- 🇮🇹
AORN San G.Moscati, Avellino, Italy
🇮🇹UO Ematologia Ospedale Dell'Angelo, Mestre, VE, Italy
🇮🇹Divisione di Ematologia, Policlinico Careggi, Firenze, Italy
Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- Drug: dose dense ABVD
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 100
- Registration Number
- NCT02247869
- Locations
- 🇮🇹
Oncologia Medica A Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
🇮🇹U.O. Oncoematologia Ospedale "Andrea Tortora", Pagani, Salerno, Italy
🇮🇹UO Ematologia Ospedale San Donato, Arezzo, Italy
BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV
- Conditions
- Relapsed/Refractory Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 13
- Registration Number
- NCT02244021
- Locations
- 🇮🇹
Ematologia, IRCCS AOU San Martino-IST, Genova, Italy
🇮🇹SC Ematologia - Azienda Ospedaliera AO Città della Salute e della Scienza, Torino, Italy
🇮🇹Istituto di Ematologia "L. & A. Seragnoli" , Policlinico S. Orsola Malpighi, Bologna, Italy
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 20
- Registration Number
- NCT02227433
- Locations
- 🇮🇹
ASST Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹Policlinico S.Orsola Malpighi, Bologna, Italy
🇮🇹Irccs Centro Di Riferimento Oncologico Di Aviano (Pn), Aviano, Italia, Italy
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
- Conditions
- Peripheral T-cell Lymphomas (PTCL)PTCL-NOSAngioimmunoblastic T-cell Lymphoma (AITL)ALK- Anaplastic Large Cell Lymphoma (ALCL)Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin
- Interventions
- Drug: Ro-CHOEP-21 (PHASE I)Drug: Ro-CHOEP-21 (PHASE II)
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 89
- Registration Number
- NCT02223208
- Locations
- 🇮🇹
Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, MI, Italy
🇮🇹AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello), Palermo, PA, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola, Meldola, FC, Italy